Company intelligence / Profile preview

DABBEL

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Double Bond Pharmaceutical develops novel therapies for brain cancer, liver cancer, and pneumonia using its proprietary BeloGal® drug delivery platform. Lead programs include SI‑053 for glioblastoma and SA‑033 for liver cancers. Belopenem targets bacterial pneumonia. The company’s approach aims to increase efficacy while reducing toxicity by targeted organ-specific drug delivery.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeHydrogel-based drug delivery therapyDrug delivery system
Industry: Biotech

Beyond the preview

Go deeper on DABBEL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DABBEL.

Explore the full profile